| Document |
Document Title |
|
WO/2002/020526A2 |
Disclosed are cyclic and acyclic amidines, pharmaceutical compositions containing such amidines, and their use in treating or preventing progesterone receptor mediated diseases or conditions, such as osteopenia and osteoporosis.
|
|
WO/2002/020521A1 |
The invention relates to the use of compounds of general formula (I) wherein R?1¿ to R?5¿ are independently selected from the group consisting of hydrogen, branched and unbranched C¿1-?C¿4-?-alkyl groups, branched and unbranched C¿1...
|
|
WO/2002/016356A2 |
The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in ...
|
|
WO/2002/015662A2 |
The invention provides compounds of Formula (I): These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in ...
|
|
WO/2002/016357A2 |
The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in ...
|
|
WO/2002/017358A2 |
The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in ...
|
|
WO/2002/016355A2 |
The invention provides compound of Formula (I): These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in w...
|
|
WO/2002/015906A1 |
The present invention relates to a class of compounds of formula (I) and (II): wherein R¿1? is hydrogen; linear or branched C¿1?-C¿15? alkyl; C¿1?-C¿15? alkenyl; C¿3?-C¿6? cycloalkyl; mono, di, tri, tetra, penta substituted aryl o...
|
|
WO/2002/016358A2 |
The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in ...
|
|
WO2001058869B1 |
Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leuk...
|
|
WO/2002/014311A2 |
Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptabl...
|
|
WO/2002/010096A1 |
One aspect of the present invention relates to a method for the kinetic resolution of racemic and diastereomeric mixtures of chiral compounds. The critical elements of the method are: a non-racemic chiral tertiary-amine-containing cataly...
|
|
WO/2002/010146A1 |
Compounds of formula (I) in which: each A is independently hydrogen, C¿1-6?alkyl optionally substituted by hydroxyl, C¿1-6?alkoxy, C¿1-6?alkenyl or C¿1-6?acyl group or a halogen atom or hydroxyl, CN or CF¿3? group; R3 is hydrogen, m...
|
|
WO/2002/010177A1 |
The present invention comprises compounds, compositions thereof, and methods capable of delivering inositol hexaphosphate (IHP) to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, comp...
|
|
WO/2002/002556A2 |
The invention is directed to aza-bridged-bicyclic compounds having Formula (I): Formula (I) and pharmaceutically acceptable salts thereof. The compounds are useful $g(a)4 integrin receptor antagonists and, in particular, $g(a)4$g(b)1 and...
|
|
WO/2002/000656A2 |
Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents. In particular, the invention relates to compounds that are potent and selective inhibitors of cyclic guanosine 3'...
|
|
WO/2002/000652A1 |
The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, CI, Br, I, (C¿1?-C¿4?)-alkylthio, (C¿1?-C¿4?)-alkoxyl, (C¿1?-C¿4?)-alkoxyl substituted by one or several F radicals, car...
|
|
WO/2001/096279A1 |
The invention relates to a method for producing derivatives of 3,3-diarylpropylamines of general formula (I) and sterically highly pure, stable intermediate products, and to their use for producing pharmaceutical compositions.
|
|
WO2001046188B1 |
The present invention provides methods for purifying, identifying and using optically active isomers of quinine and quinidine as well as compositions comprising such optically active isomers. Such optically active isomers having desired ...
|
|
WO/2001/092280A1 |
This invention relates to compounds of formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R?1¿, R?2¿, R?3¿ and R?10¿ are as defined herein. The compounds of formula (1) are antibacter...
|
|
WO/2001/090107A1 |
The invention concerns quaternary ammonium compounds whereof the nitrogen bears a fluorine atom. Said ammonium compounds have an asymmetric carbon atom which is spaced from the ammonium function by not more than five members. The inventi...
|
|
WO/2001/087838A1 |
The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R?1¿, R?2¿, R?3¿, R?4¿, R?5¿,...
|
|
WO/2001/085727A1 |
The invention provides compounds of formula (I) wherein n, A, R¿1?, R¿2? and R¿3? are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
|
|
WO/2001/081355A1 |
The present invention relates to the syntheses and structural elucidation of Combretastatin A1-Phosphate Prodrugs and Combretastatin B1-Phosphate Prodrugs and the utilization of those prodrugs in the treatment of neoplastic diseases. The...
|
|
WO/2001/077105A1 |
The invention concerns dual molecules formed by coupling products with a molecule residue exhibiting antimalarial activity, 1 or 2 C¿1?-C¿5? alkylene chains comprising an amine, amide, sulphonamide, carboxyl, ether or thioether functio...
|
|
WO/2001/076571A2 |
The use of [R-(Z)]-$g(a)-(methoxyimino)-$g(a)-(1-azabicyclo[2.2.2]oct-3
-yl)acetonitrile or a pharmaceutically accetpable salt thereof for the treatment of anxiety.
|
|
WO/2001/068599A2 |
A dosing form for at least one solid reagent for use in conventional organic and inorganic synthesis, in parallel synthesis, and in split and mix synthesis in combinatorial chemistry is provided as compressed tablets each containing the ...
|
|
WO/2001/064656A1 |
Pyrimidine derivatives of formula (I) wherein Q¿1?, Q¿2?, G and R?1¿ are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical c...
|
|
WO/2001/062758A1 |
The invention provides pteridine compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. Formula (I) in which A is a group of formula (a) or (b).
|
|
WO/2001/060821A1 |
A compound of formula (I), wherein A represents (II), (III), (IV) or (V), D represents oxygen or sulfur; E represents a single bond, oxygen, sulfur, or NR?10¿; R represents hydrogen or methyl; Ar?1¿ represents a 5- or 6-membered aromat...
|
|
WO/2001/058421A1 |
The invention concerns cosmetic compositions, in particular for preventing and treating skin ageing, characterised in that they contain a combination of a first thiosalicylic derivative active principle of general formulae (I) and (I") w...
|
|
WO/2001/057008A1 |
The present invention is directed to a compound of formula (I), racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs...
|
|
WO1999063937A9 |
Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptogramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more prot...
|
|
WO/2001/044213A1 |
The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R?1¿ and R?2¿ are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their p...
|
|
WO/2001/042213A1 |
The invention relates to urea compounds that are muscarinic receptor antagonists and agonists, pharmaceutical compositions comprising such compounds, and methods of preparing these compounds.
|
|
WO/2001/042212A1 |
This invention relates to hindered carbamate derivatives that are muscarinic receptor antagonists and antagonists, pharmaceutical compositions comprising such compounds, and methods of preparing these compounds.
|
|
WO/2001/036417A1 |
This invention relates to new use of a compound of general formula (I) wherein: A represents (II), (III), (IV), (V), (VI); D represents oxygen, or sulfur; R?1¿ represents hydrogen or methyl; R?2¿ represents hydrogen, or C¿1?-C¿4? alk...
|
|
WO/2001/034610A1 |
The invention is based on the discovery that compounds of Formula (I) are unexpectedly highly potent and selective inhibitors of the adenosine A¿1? receptor. Adenosine A¿1? antagonists can be useful in the prevention and/or treatment o...
|
|
WO/2001/032177A1 |
Novel 2-aza-bicyclo[2.2.2]octanes substituted in the 2-position are effective as NMDA NR2B antagonists useful for relieving pain.
|
|
WO/2001/032264A1 |
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryl olefinic azacyclic compounds and aryl acetylenic azacylic compou...
|
|
WO/2001/029000A2 |
The present application describes modulators of CCR3 of formula (I): A-E-NR?1¿-G, or pharmaceutically acceptable salt forms thereof, wherein: A is selected from (a), (b), (c) and (d). G is selected from -C(O)R?3¿, -C(O)NR?2¿R?3¿, -C(...
|
|
WO/2001/029034A1 |
A compound of formula (I) wherein A represents (II), (III), (IV), (V) or (VI); R represents hydrogen or methyl; R?1¿ and R?2¿ are independently hydrogen, or C¿1?-C¿4? alkyl; R?3¿ and R?4¿ are independently hydrogen, C¿1?-C¿4? alk...
|
|
WO/2001/025215A2 |
The invention relates to a method for selectively dissociating cyclic carboxylic acid anhydrides of the formula (I), wherein R represents benzyl, alkyl having 1 to 6 carbon atoms or aryl, to give the corresponding semi-esters. According ...
|
|
WO/2001/023383A1 |
Compounds represented by general formula (I), salts thereof, or hydrates of both, useful as excellent squalene synthase inhibitors wherein R?1¿ is hydrogen or hydroxyl; HAr is an optionally substituted aromatic heterocycle; Ar is an opt...
|
|
WO/2001/016107A1 |
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need arylalkyloxyalkylamine and arylalkylthioalkylamine compounds, including arylm...
|
|
WO/2001/015532A1 |
The use of azabicyclo and azacyclo oxime and amine compounds of the formula (I) to (IV) wherein the symbols and indices have the meanings given in the specification for controlling animal pests.
|
|
WO/2001/014310A1 |
Pleuromultilin $g(b)-ketoesters of Formula (IA) or (IB), in which R?1¿ is a nitrogen containing heterocycle, an optionally substituted aryl or optionally substituted heteroaryl group, or CH¿2?R?5¿; R?2¿ is vinyl or ethyl; R?3¿ is H,...
|
|
WO/2001/011968A2 |
Heterocyclic spiro compounds of formula (I) or salts thereof, wherein the symbols have the meaning given in the description, are useful for combatting animal pest.
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
WO/2001/004118A2 |
A compound according to formula (I) wherein z© is a phenyl ring, a C¿4? to C¿9? heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; which shows high affinity...
|
